Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Honey in Orabase (1:1) is an investigational topical mucoadhesive paste formulation developed for the treatment of symptomatic oral lichen planus (OLP), particularly the atrophic and erosive forms. Developed by researchers at Dar Al Uloom University, the formulation consists of a 50% concentration of honey blended with Orabase, a protective adhesive paste base. Honey serves as the active therapeutic agent, providing natural anti-inflammatory, antimicrobial, and antioxidant properties that facilitate wound healing and alleviate pain. The Orabase component acts as a mucoadhesive vehicle, ensuring prolonged contact of the honey with the oral mucosa. Clinical trials have evaluated this natural product-based therapy against standard corticosteroid treatments, such as triamcinolone acetonide 0.1%, to assess its efficacy in reducing lesion size and improving patient quality of life.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Honey in Orabase (1:1).